Trade Sangamo Therapeutics

Sangamo Therapeutics, Inc. (formerly known as Sanjammu Biological Sciences, Inc.) is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to fight hemophilia and other genetic diseases. company was founded in 1995 in Richmond, California. It was originally known as Sangamo Bioscience, before changing names in 2017. In September 2018, it had 182 employees. Sandy Macrae is the president. In 2018, Edward Rebar became Senior Vice President and Chief Technology Officer of Sangamo. Sangamo applies technology for the treatment of hemophilia B and lysosumi storage diseases including the first type mucopolysaccharidosis (Herler syndrome) and mucopolysaccharidosis type II (Hunter syndrome). The FDA granted Sangamo fast track designation to SB-525, a gene therapy candidate for Hemophilia A. in its partnership with Pfizer in 2017, Sangamo Bioverativ is used in hemoglobin diseases such as beta thalassemia and sickle cell disease. It also develops the technique of editing zinc finger genes. In February 2019, medical scientists working with Sangamo Therapeutics announced the first "in-body" treatment for human gene editing to permanently alter DNA - in a patient with Hunter syndrome. As of February 2019, clinical trials conducted by Sangamo involving gene editing using zinc finger nuclei were ongoing.